SEC Form 4	
------------	--

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed purculant to Section 16(a) of the Securities Evolution Act of 1024

OMB APPROVAL

l	OMB Number:	3235-0287
	Estimated average bur	den
	hours per response:	0.5

		File	or Section 30(h) of the Investment Company Act of 1940							
Bizily Scott (Last)	(First) (Middle) D MOLECULAR THERAPEUTICS, INC. HORTON STREET #455		2. Issuer Name and Ticker or Trading Symbol <u>4D Molecular Therapeutics, Inc.</u> [FMDT] 3. Date of Earliest Transaction (Month/Day/Year) 06/08/2023	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Chief Legal and HR Officer						
5858 HORTON (Street) EMERYVILLE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Interview 10b5-1(c). See I	ant to a contract, instruction or written plan that is intended to						
		Table I - Non-Deriv	ative Securities Acquired, Disposed of, or Benef	icially Owned						

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	06/08/2023		M ⁽¹⁾		3,750	A	\$8.04	5,487	D	
Common Stock	06/08/2023		S ⁽¹⁾		3,750	D	\$20.85	1,737	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		of Deri Sec Acq (A) (Disp of (I	posed D) :tr. 3, 4			Amount of		Amount of Derivative Securities Security Underlying (Instr. 5) Derivative Security		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$8.04	06/08/2023		М			3,750	(2)	08/31/2032	Common Stock	3,750	\$ <mark>0</mark>	48,750	D	

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1.

<u>/s/ August Moretti as Attorney-</u> 06/12/2023

in-fact for Scott Bizily

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.